TargED Biopharmaceuticals B.V., founded in 2020 as a spin-out from University Medical Center Utrecht, is focused on TGD001, an antibody-enzyme fusion protein that binds von Willebrand factor (VWF) and degrades both VWF and fibrin to dissolve clots. The therapy has completed a Phase 1 first-in-human study that showed a favorable safety profile with no spontaneous bleeding events and potent thrombolytic activity. With its latest funding, the company will initiate two Phase 1/2 clinical studies targeting acute ischemic stroke and thrombotic microangiopathies, expanding trial sites across Europe and the U.S. and aiming for first data in 2026. Unlike approved thrombolytics that target a single pathway, TGD001 leverages the ubiquitous presence of VWF to enable broad clot dissolution. TargED has raised over €60 million in Series A financing to date and also received a blended-finance grant from the European Innovation Council Accelerator in 2025. The fresh capital strengthens its balance sheet and accelerates clinical development toward demonstrating proof-of-concept in multiple life-threatening indications.

Total raised

$70M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025